Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
Want to see NAUT full AI Analyst Report?
NAUT Stock Chart & Stats
$3.03
$0.07(3.48%)
At close: 4:00 PM EST
$3.03
$0.07(3.48%)
Day’s Range― - ―
52-Week Range$0.62 - $4.31
Previous CloseN/A
Volume21.91K
Average Volume (3M)394.63K
Market Cap
$317.70M
Enterprise Value$330.66M
Total Cash (Recent Filing)$95.87M
Total Debt (Recent Filing)$28.87M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 04, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding126,564,476
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-52.35
Enterprise Value/Ebitda-6.33
Forecast
1Y Price Target
$4.00Price Target Upside32.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Technical Validation & Unique PlatformPublic Voyager debut with positive community feedback represents tangible external validation of Nautilus' core instrument. Durable impact: a validated, differentiated platform strengthens credibility with research and pharma customers, easing later instrument adoption and consumables monetization once commercial sales begin.
Early Access Program And Assay ReadinessAn operational Early Access program and a validated Tau assay provide a structured route to refine workflows and generate customer data. Over the medium term this builds scientific referenceability, shortens adoption cycles, and lowers commercialization risk by aligning product development with early user feedback.
Improved Cash Position And RunwayA $156.1M cash balance and reduced 2025 burn extend runway into 2027, giving management time to complete instrument validation and begin installations. This financial cushion supports multi-year commercialization investments and reduces immediate refinancing pressure while product-market fit is established.
Bears Say
Pre-commercial Profile; No RevenueWith no trailing revenue, Nautilus lacks real-world proof of its recurring consumables model and has no operating leverage. Persistent negative gross profit and heavy losses mean the firm must convert instrument placements into repeat consumable spend to achieve durable profitability.
No Sales Organization TodayAbsent a sales force, the company faces a meaningful execution gap between technical validation and commercial revenue. Building and scaling a commercial organization takes quarters to years, creating durable risk that technical wins may not convert quickly into sustainable customer contracts and recurring revenue.
Planned 2026 Spend And Higher Cash BurnA planned increase in 2026 operating expenses and cash burn raises funding needs during the commercialization build-out. If instrument placements or consumables monetization lag, the higher burn elevates dilution or refinancing risk and tightens the window to achieve self-sustaining cash generation.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.62 and its highest was $4.31 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $317.70M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Aug 04, 2026 which is in 96 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Apr 28, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.025.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.14.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 126,564,476 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went up 0.778%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nautilus Biotechnolgy Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (32.01% Upside)
$4.00 (32.01% Upside)
Insider Transactions
Bought Shares
Worth $65.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.20%
12-Months-Change
Fundamentals
Return on Equity
-33.64%
Trailing 12-Months
Asset Growth
-21.27%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful technical progress, strong external validation, the successful public debut of the Voyager instrument, the early launch of an Early Access Program (Tau assay) and disciplined expense reductions that improved cash burn and extended runway through 2027. Offsetting these positives are limited near-term revenue (modest 2026 services revenue targeted at ~$0.5M), no current sales organization, and a planned increase in 2026 operating expenses and cash burn as the company invests to advance commercialization. On balance, the developments point to a company transitioning from development to early customer engagement with tangible validation and a clear commercialization timeline, though revenue and commercial execution risks remain in the near term.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$4.00
▲(32.01% Upside)
Technical Analysis
Ownership Overview
35.45% Insiders
2.59% Mutual Funds
0.82% Other Institutional Investors
59.08% Public Companies and
Individual Investors